Fusion protein as well as preparation method and application thereof
By developing fusion proteins containing TNF receptors, OPG and Fc fragments, the problem of insufficient prevention of bone loss in the treatment of rheumatoid arthritis has been solved, and effective inhibition of inflammation and bone loss has been achieved.
Patent Information
- Application Number
- CN202410937377.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-13
- Filing Date
- 2021-01-13
- Publication Date
- 2024-11-19
AI Technical Summary
Although existing TNFα blockers can improve inflammation in the treatment of rheumatoid arthritis, they lack effective prevention and treatment effects on focal bone erosion and systemic bone loss.
A fusion protein was developed, including TNF receptor, OPG or its active fragments and Fc fragments, to inhibit TNFα-induced apoptosis and RANKL-induced monocyte differentiation, thereby improving inflammation and preventing bone loss.
This fusion protein significantly inhibits TNFα and RANKL-related apoptosis and bone loss, significantly improves the inflammatory status of patients with rheumatoid arthritis, and effectively prevents bone loss.
Smart Images

Figure BDA0004941734300000171 
Figure BDA0004941734300000221 
Figure BDA0004941734300000231
Abstract
Description
[0001] This application is a divisional application of the invention patent application with application date of January 13, 2021, application number 202180001300.X, and invention name “A fusion protein, its preparation method and use”. Technical Field
[0002] The present invention relates to the biological and pharmaceutical fields, and more specifically to a fusion protein and a preparation method and application thereof. Background Art
[0003] Autoimmune disease is an immune-mediated disease, a state in which the immune system responds positively to the host's own antigens, causing pathological damage to tissues or organs, affecting their physiological functions, and ultimately leading to various clinical symptoms. Rheumatoid arthritis (RA) is the most common and most common autoimmune disease, which causes damage to the synovium, articular cartilage and bones. RA is caused and maintained by a series of proinflammatory cytokines that interact with each other, among which TNFα is the key inflammatory mediator cytokine in patients with inflammatory arthritis. Currently, there are a variety of drugs that inhibit the function of TNFa (TNFa blockers) in clinical treatment of various autoimmune diseases.
[0004] Arthritis is a chronic soft tissue inflammation that is usually accompanied by joint destruction. Immune-mediated arthritis usually causes focal bone erosions in the inflamed joints, which is mainly caused by excessive osteoclast activity mediated by the receptor activator NF-κB ligand (RANKL). RANKL is an important mediator of bone resorption, and osteoprotegerin (OPG) is a decoy receptor for RANKL, a soluble protein that can specifically bind to RANKL, and is a physiological inhibitor of RANKL.
[0005] However, although current drugs can improve inflammation in RA patients, they have no or very limited preventive and therapeutic effects on focal bone erosion in inflamed joints and systemic bone loss.
[0006] Therefore, there is an urgent need in the art to develop drugs that can not only improve inflammation in RA patients, but also prevent focal bone erosion and systemic bone loss caused by inflammation. Summary of the invention
[0007] The purpose of the present invention is to provide a drug that can not only improve inflammation in RA patients, but also prevent focal bone erosion and systemic bone loss caused by inflammation.
[0008] In a first aspect of the present invention, a fusion protein is provided, which comprises the following elements fused together: (a) TNF receptor or an active fragment thereof; (b) OPG or an active fragment thereof; and optionally (c) an Fc fragment.
[0009] In another preferred embodiment, the fusion protein retains the biological activities of the above elements (a) and (b).
[0010] In another preferred embodiment, the TNF receptor is selected from the following group: TNFR2, TNFR1, or a combination thereof.
[0011] In another preferred embodiment, the TNF receptor is derived from humans or non-human mammals, more preferably from rodents (such as mice, rats), primates and humans.
[0012] In another preferred embodiment, the TNF receptor includes wild type and mutant type.
[0013] In another preferred embodiment, the TNF receptor comprises a full-length, mature form of the TNF receptor, or an active fragment thereof.
[0014] In another preferred embodiment, the TNF receptor also includes a derivative of TNF receptor.
[0015] In another preferred embodiment, the TNF receptor derivatives include modified TNF receptors, protein molecules whose amino acid sequences are homologous to natural TNF receptors and have natural TNF receptor activity, dimers or polymers of TNF receptors, and fusion proteins containing TNF receptor amino acid sequences.
[0016] In another preferred embodiment, the modified TNF receptor is a PEGylated TNF receptor.
[0017] In another preferred embodiment, the "protein molecule whose amino acid sequence is homologous to the natural TNF receptor and has natural TNF receptor activity" refers to a protein molecule whose amino acid sequence has ≥85% homology, preferably ≥90% homology, more preferably ≥95% homology, and optimally ≥98% homology compared to the TNF receptor; and has TNF receptor activity.
[0018] In another preferred embodiment, the TNF receptor includes a first domain, a second domain, a third domain, and / or a fourth domain.
[0019] In another preferred example, the first domain, the second domain, the third domain, and / or the fourth domain are each independently a cysteine-rich region (CRD).
[0020] In another preferred embodiment, the TNF receptor is the second domain and the third domain of the extracellular region of the TNF receptor, or the extracellular region of the TNF receptor containing the second domain and the third domain.
[0021] In another preferred embodiment, the TNF receptor contains or has positions 1-257, or positions 23-257, or positions 77-162, or positions 205-257 of the TNFR2 amino acid sequence (SEQ ID NO.: 4).
[0022] In another preferred embodiment, the OPG is derived from humans or non-human mammals, more preferably from rodents (such as mice, rats), primates and humans.
[0023] In another preferred example, the OPG includes wild type and mutant type.
[0024] In another preferred embodiment, the OPG comprises a full-length, mature form of OPG, or an active fragment thereof.
[0025] In another preferred embodiment, the OPG also includes derivatives of OPG.
[0026] In another preferred embodiment, the OPG derivatives include modified OPG, protein molecules whose amino acid sequences are homologous to natural OPG and have natural OPG activity, dimers or polymers of OPG, and fusion proteins containing the amino acid sequence of OPG.
[0027] In another preferred embodiment, the modified OPG is PEGylated OPG.
[0028] In another preferred embodiment, the "protein molecule whose amino acid sequence is homologous to natural OPG and has natural OPG activity" refers to a protein molecule whose amino acid sequence has ≥85% homology with OPG, preferably ≥90% homology, more preferably ≥95% homology, and optimally ≥98% homology; and has OPG activity.
[0029] In another preferred example, the OPG includes a first domain, a second domain, a third domain, and / or a fourth domain.
[0030] In another preferred example, the first domain, the second domain, the third domain, and / or the fourth domain are each independently a cysteine-rich region (CRD).
[0031] In another preferred embodiment, the OPG is the second domain, the third domain and the fourth domain of the OPG extracellular region, or the OPG extracellular region containing the second domain, the third domain and the fourth domain.
[0032] In another preferred embodiment, the OPG contains or has positions 1-194, or positions 22-194, or positions 22-194 of the OPG amino acid sequence (SEQ ID NO.: 5).
[0033] In another preferred embodiment, the Fc fragment is derived from human or non-human mammals, more preferably from rodents (such as mice, rats), primates and humans.
[0034] In another preferred embodiment, the Fc fragment is the Fc fragment of immunoglobulin IgG, preferably the Fc part of IgG1.
[0035] In another preferred embodiment, the Fc fragment includes a natural Fc fragment and an Fc mutant.
[0036] In another preferred embodiment, the Fc fragment contains or has the amino acid sequence of human IgG1 (accession number: UniProtKB-P01857) from position 99 (Glu) to position 330 (Lys).
[0037] In another preferred embodiment, the Fc fragment contains or has positions 487-718 of SEQ ID NO.:1.
[0038] In another preferred embodiment, the Fc fragment contains or has positions 430-661 of SEQ ID NO.:2.
[0039] In another preferred embodiment, the amino acid sequence of the Fc fragment is shown in SEQ ID NO.:3.
[0040] In another preferred embodiment, the fusion protein has a structure shown in the following formula I or II:
[0041] XYZ(I)
[0042] YXZ(II);
[0043] In the formula,
[0044] X is a TNF receptor or an active fragment thereof;
[0045] Y is OPG or an active fragment thereof;
[0046] Z is an optional Fc fragment;
[0047] "-" represents a peptide bond or a peptide linker connecting the above elements.
[0048] In another preferred embodiment, any two of X, Y and Z are connected in a head-to-head, head-to-tail, tail-to-head or tail-to-tail manner.
[0049] In another preferred embodiment, the "head" refers to the N-terminus of a polypeptide or a fragment thereof, especially the N-terminus of a wild-type polypeptide or a fragment thereof.
[0050] In another preferred embodiment, the "tail" refers to the C-terminus of a polypeptide or a fragment thereof, especially the C-terminus of a wild-type polypeptide or a fragment thereof.
[0051] In another preferred embodiment, the length of the peptide linker is 0-20 amino acids, preferably, 0-10 amino acids.
[0052] In another preferred embodiment, the fusion protein is a homodimer.
[0053] In another preferred embodiment, the fusion protein is selected from the following group:
[0054] (A) a polypeptide having an amino acid sequence as shown in SEQ ID NO: 1 or 2;
[0055] (B) a polypeptide having ≥80% homology (preferably, ≥90% homology; more preferably ≥95% homology; most preferably, ≥97% homology, such as 98% or more, 99% or more) with the amino acid sequence of SEQ ID NO: 1 or 2, and the polypeptide has (a) inflammation inhibition activity or (b) osteoporosis and / or bone loss inhibition activity;
[0056] (C) A derivative polypeptide formed by substituting, deleting or adding 1 to 5 amino acid residues of the amino acid sequence shown in SEQ ID NO: 1 or 2, and retaining (a) inflammation inhibition activity or (b) osteoporosis and / or bone loss inhibition activity.
[0057] In another preferred embodiment, the amino acid sequence of the fusion protein is as shown in SEQ ID NO.: 1 or 2.
[0058] The second aspect of the present invention provides an isolated polynucleotide, wherein the polynucleotide encodes the fusion protein described in the first aspect of the present invention.
[0059] In another preferred embodiment, the polynucleotide further contains auxiliary elements selected from the following groups on the flank of the ORF of the mutant protein or fusion protein: a signal peptide, a secretory peptide, a tag sequence (such as 6His), or a combination thereof.
[0060] In another preferred embodiment, the polynucleotide is selected from the following group: a DNA sequence, an RNA sequence, or a combination thereof.
[0061] The third aspect of the present invention provides a vector comprising the polynucleotide described in the second aspect of the present invention.
[0062] In another preferred embodiment, the vector comprises one or more promoters, which are operably connected to the nucleic acid sequence, enhancer, transcription termination signal, polyadenylation sequence, replication origin, selective marker, nucleic acid restriction site, and / or homologous recombination site.
[0063] In another preferred embodiment, the vector includes a plasmid or a viral vector.
[0064] In another preferred embodiment, the viral vector is selected from the following group: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, herpes virus, SV40, poxvirus, or a combination thereof.
[0065] In another preferred embodiment, the vector includes an expression vector, a shuttle vector, and an integration vector.
[0066] The fourth aspect of the present invention provides a host cell, wherein the host cell contains the vector described in the third aspect of the present invention, or the polynucleotide described in the second aspect of the present invention is integrated into its genome.
[0067] In another preferred embodiment, the host cell is a eukaryotic cell, such as a yeast cell, a plant cell or a mammalian cell (including human and non-human mammals).
[0068] In another preferred embodiment, the host cell is a prokaryotic cell, such as Escherichia coli.
[0069] In another preferred embodiment, the yeast cell is selected from yeast of one or more sources of the following group: Pichia pastoris, Kluyveromyces, or a combination thereof; preferably, the yeast cell includes: Kluyveromyces, more preferably Kluyveromyces marxianus, and / or Kluyveromyces lactis.
[0070] In another preferred embodiment, the host cell is selected from the following group: Escherichia coli, wheat germ cells, insect cells, SF9, SP2 / 0, Hela, HEK293, CHO (such as CHOKS), yeast cells, or a combination thereof.
[0071] The fifth aspect of the present invention provides a method for producing the fusion protein according to the first aspect of the present invention, wherein the method comprises the steps of:
[0072] Cultivating the host cell according to the fourth aspect of the present invention under conditions suitable for expression, thereby expressing the fusion protein; and / or
[0073] and isolating or purifying the fusion protein.
[0074] The sixth aspect of the present invention provides a pharmaceutical composition, which contains the fusion protein described in the first aspect of the present invention and a pharmaceutically acceptable carrier thereof.
[0075] In another preferred embodiment, the pharmaceutical composition further comprises other drugs for inhibiting inflammatory activity.
[0076] In another preferred embodiment, other drugs for inhibiting inflammatory activity are selected from the following group: hormone drugs, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, small molecule targeted drugs, biological agents, or a combination thereof.
[0077] In another preferred embodiment, the hormone drug is selected from the following group: hydrocortisone, prednisone, prednisolone, dexamethasone, or a combination thereof.
[0078] In another preferred embodiment, the nonsteroidal anti-inflammatory drug is selected from the group consisting of aspirin, indomethacin, naproxen, ibuprofen, diclofenac, loxoprofen, meloxicam, celecoxib, etoricoxib, parecoxib, or a combination thereof.
[0079] In another preferred embodiment, the immunosuppressive drug is selected from the group consisting of methotrexate, cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus, leflunomide, or a combination thereof.
[0080] In another preferred embodiment, the small molecule targeted drug is selected from the following group: tofacitinib, baricitinib, or a combination thereof.
[0081] In another preferred embodiment, the biological agent is selected from the following group: etanercept, certolizumab pegol, adalimumab, golimumab, infliximab, tocilizumab, secukinumab, ustekinumab, canakinumab, anakinra, rilonacept, abatacept, rituximab, belimumab, or a combination thereof.
[0082] The seventh aspect of the present invention provides a use of the fusion protein described in the first aspect of the present invention, the polynucleotide described in the second aspect of the present invention, the vector described in the third aspect of the present invention, and the host cell described in the fourth aspect of the present invention for preparing a composition or preparation, wherein the composition or preparation is used for (i) preventing and / or treating infectious diseases; and / or (ii) preventing and / or treating autoimmune diseases; and / or (iii) preventing and / or treating osteoporosis or loss; and / or (iv) preventing and / or treating tumor-related diseases.
[0083] In another preferred embodiment, the infectious disease includes septic shock (such as LPS-induced septic shock).
[0084] In another preferred embodiment, the autoimmune disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, or a combination thereof.
[0085] In another preferred embodiment, the osteoporosis or loss is selected from the group consisting of osteoporosis and / or loss caused by rheumatoid arthritis, osteoporosis in postmenopausal women, or a combination thereof.
[0086] In another preferred embodiment, the tumor-related disease is selected from the following group: multiple myeloma, bone-related bone metastatic solid tumor, or a combination thereof.
[0087] In another preferred embodiment, the composition or preparation is also used for one or more purposes selected from the following group:
[0088] (a) Inhibit TNFa-induced cell apoptosis;
[0089] (b) inhibiting TNFa-induced immune activation;
[0090] (c) inhibiting TRAIL-induced cell apoptosis;
[0091] (d) inhibiting RANKL-induced monocyte-macrophage differentiation;
[0092] (e) Inhibition of RANKL-induced osteoclast formation.
[0093] In another preferred embodiment, the cells are selected from the group consisting of fibroblasts, monocyte macrophages, vascular endothelial cells, or a combination thereof.
[0094] In another preferred embodiment, the composition is a pharmaceutical composition.
[0095] The eighth aspect of the present invention provides a method for inhibiting cell apoptosis, comprising the steps of:
[0096] Cells are cultured in the presence of the fusion protein described in the first aspect of the present invention, thereby inhibiting cell apoptosis.
[0097] In another preferred embodiment, the cells are selected from the group consisting of fibroblasts, blood tumor cells, solid tumor cells, or a combination thereof.
[0098] In another preferred embodiment, the blood tumor cells are selected from the group consisting of B cell malignant tumor cells, acute myeloid leukemia cells, Hodgkin's lymphoma cells, T cell malignant tumor cells, multiple myeloma cells, or a combination thereof.
[0099] In another preferred embodiment, the solid tumor cells are selected from the group consisting of breast cancer cells, non-small cell lung cancer cells, liver cancer cells, colon cancer cells, gastric cancer cells, or a combination thereof.
[0100] In another preferred embodiment, the cells are cells cultured in vitro.
[0101] In another preferred embodiment, the method is non-therapeutic and non-diagnostic.
[0102] In another preferred embodiment, the cell apoptosis includes TNFa-induced cell apoptosis; and / or TRAIL-induced cell apoptosis.
[0103] The ninth aspect of the present invention provides a method for inhibiting the differentiation of mononuclear macrophages, comprising the steps of:
[0104] In the presence of the fusion protein described in the first aspect of the present invention, mononuclear macrophages are cultured to inhibit the differentiation of mononuclear macrophages.
[0105] In another preferred embodiment, the mononuclear macrophages are cells cultured in vitro.
[0106] In another preferred embodiment, the method is non-therapeutic and non-diagnostic.
[0107] In another preferred embodiment, the differentiation of mononuclear macrophages is RANKL-induced differentiation of mononuclear macrophages.
[0108] The tenth aspect of the present invention provides a method for preventing and / or treating a disease, comprising the steps of: administering the fusion protein described in the first aspect of the present invention to a subject in need thereof.
[0109] In another preferred embodiment, the fusion protein is administered in the form of monomers and / or dimers.
[0110] In another preferred embodiment, the subject is a human.
[0111] In another preferred embodiment, the disease is selected from the following group: infectious diseases, autoimmune diseases, osteoporosis or bone loss, tumor-related diseases, or a combination thereof.
[0112] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0113] Figure 1 The diagram is a schematic diagram of the structure of the fusion protein OPG-TNFR2-Fc and TNFR2-OPG-Fc. OPG-TNFR2-Fc contains (from N-terminus to C-terminus): OPG amino acid sequence 22-194 including 4 CRDs, TNFR2 amino acid sequence 23-257 including 4 CRDs, and IgG1 Fc. TNFR2-OPG-Fc contains (from N-terminus to C-terminus): TNFR2 amino acid sequence 23-257 including 4 CRDs, OPG amino acid sequence 22-194 including 4 CRDs, TNFR2 amino acid sequence 203-257, and IgG1 Fc.
[0114] Figure 2 The fusion protein was analyzed by reducing and non-reducing denaturing protein gel SDS-PAGE. The fusion protein purified by Protein A affinity chromatography was analyzed and identified by 6% non-reducing denaturing SDS-PAGE (A) and 10% reducing denaturing SDS-PAGE (B). 1: human IgG1; 2: OPG-TNFR2-Fc; 3: TNFR2-OPG-Fc. 5 mg was loaded for each sample.
[0115] Figure 3 HPLC-SEC analysis of the fusion protein is shown. The fusion protein was analyzed using a HPLC-SEC (TSKgel G3000SWXL) column. The red curve represents OPG-TNFR2-Fc; the green curve represents TNFR2-OPG-Fc. The molecular weight is indicated by the blue curve.
[0116] Figure 4 The results of ELISA studies of in vitro binding to recombinant human TNFa are shown.
[0117] Figure 5 The results of ELISA studies of in vitro binding to recombinant human RANKL are shown.
[0118] Figure 6 The results of ELISA studies of in vitro binding of recombinant human TRAIL are shown.
[0119] Figure 7 The results of the study on inhibition of TNFa-induced apoptosis in L929 cells are shown.
[0120] Figure 8 Shown are the results of a study on inhibition of Trail-induced apoptosis in L929 cells.
[0121] Fig. 9 The results of the study on inhibition of RANKL-induced cell differentiation in RAW264.7 cells are shown.
[0122] Fig.10 The results of a study on inhibition of LPS-induced septic shock mortality in mice are shown.
[0123] FIG. 11 shows (A) reducing the incidence of inflammation induced by CIA in mice; (B) reducing the extent of inflammation induced by CIA in mice. DETAILED DESCRIPTION
[0124] After in-depth research, the inventors unexpectedly found that the fusion protein obtained by fusing (a) TNF receptor or its active fragment; (b) OPG or its active fragment; and optionally (c) Fc fragment has extremely excellent biological activity, and can significantly (a) inhibit TNFa-induced cell apoptosis; and / or (b) inhibit TRAIL-induced cell apoptosis; and / or (c) inhibit RANKL-induced mononuclear macrophage differentiation. In addition, the fusion protein has good stability and long half-life, so it helps (i) prevent and / or treat infectious diseases; and / or (ii) prevent and / or treat autoimmune diseases; and / or (iii) prevent and / or treat tumor-related diseases. The present invention was completed on this basis.
[0125] As used herein, unless otherwise specified, Fc refers to the Fc fragment of a human immunoglobulin. The term "immunoglobulin Fc region" refers to the constant region of an immunoglobulin chain, in particular the carboxyl end of the constant region of an immunoglobulin heavy chain or a portion thereof, for example, an immunoglobulin Fc region may include a combination of two or more domains of the heavy chain CH1, CH2, and CH3 and an immunoglobulin hinge region, in a preferred embodiment, the immunoglobulin Fc region used includes at least one immunoglobulin hinge region, a CH2 domain, and a CH3 domain, preferably lacking a CH1 domain.
[0126] It is known that there are many types of human immunoglobulins, such as IgA, IgD, IgE, IgM and IgG (including four subclasses, IgG1, IgG2, IgG3 and IgG4). It is within the skill of those skilled in the art to select a specific immunoglobulin Fc region from a specific immunoglobulin class and subclass. In a preferred embodiment, the immunoglobulin Fc region can be selected to include a coding sequence of a human immunoglobulin IgG4 subclass Fc region, which lacks an immunoglobulin heavy chain 1 domain (CH1) but includes a hinge region and coding sequences of two domains, CH2 and CH3.
[0127] As used herein, the terms “containing”, “having” or “including” include “comprising”, “mainly consisting of…”, “substantially consisting of…”, and “consisting of…”; “mainly consisting of…”, “substantially consisting of…” and “consisting of…” are subordinate concepts of “containing”, “having” or “including”.
[0128] As used herein, unless otherwise indicated, the fusion protein is an isolated protein that is not associated with other proteins, polypeptides or molecules and is a purified product of recombinant host cell culture or as a purified extract.
[0129] TNF receptor or its active fragment
[0130] TNFR1 and 2 belong to the TNF receptor superfamily and are type I transmembrane proteins. The molecular weights of TNFR1 and TNFR2 are 55 and 75 kDa, respectively. Their extracellular regions each contain four cysteine-rich regions, and the amino acid sequences have 23% identity. TNFR1 is widely expressed in various cells, while TNFR2 is mainly expressed in hematopoietic cells, such as T cells and natural killer cells, as well as endothelial cells, neurons, thymocytes, and mesenchymal stem cells. TNFR1 mainly binds to soluble TNFa, while TNFR2 binds to soluble TNFa and can also bind to TNFa in the form of membrane protein.
[0131] In the present invention, TNF receptors include but are not limited to TNFR2 and TNFR1. As used herein, unless otherwise specified, TNF-R2, TNFR II, and hTNFR II are used interchangeably and all refer to human tumor necrosis factor type II receptor.
[0132] OPG
[0133] OPG (osteoprotegrin) is a secretory protein with a molecular weight of about 55-60kDa. It has the function of inhibiting osteoclastogenesis and regulating bone density. OPG belongs to the tumor necrosis factor receptor superfamily (TNFR) member. Mature OPG contains 4 cysteine-rich regions, 2 death domains and 1 heparin binding domain. The cysteine-rich region is crucial for the interaction between OPG and its ligands, and the C-terminal cystein mediates the formation of homodimers. OPG is widely and continuously expressed in mesenchymal stem cells, fibroblasts and endothelial cells. OPG is also known as the decoy receptor for TNF superfamily ligands, binding to RANKL and TRAIL. TRAIL reduces the release of OPG from expressing cells, while OPG inhibits TRAIL-induced apoptosis. OPG can inhibit the function of RANKL in promoting osteoclast formation and promoting osteoclastogenesis. OPG deficiency in the human body causes juvenile Paget's disease. When there is not enough OPG to balance the functions of RANKL and RANK, it will lead to osteoporosis and vascular calcification.
[0134] Fusion Protein
[0135] As used herein, "the fusion protein of the present invention" or "polypeptide" refers to the fusion protein described in the first aspect of the present invention.
[0136] In a preferred embodiment, the fusion protein of the present invention comprises the following elements: (a) TNF receptor or its active fragment, (b) OPG or its active fragment, and optionally (c) Fc fragment. In the fusion protein of the present invention, between the elements (such as element a and element b, element b or element c), there may or may not be a linking sequence. The linking sequence is usually a sequence that does not affect the two proteins.
[0137] In another preferred embodiment, the structure of the fusion protein is as shown in XYZ (I) or YXZ (II), wherein X is TNF receptor or its active fragment; Y is OPG or its active fragment; and Z is an optional Fc fragment.
[0138] In another preferred embodiment, the fusion protein has an amino acid sequence as shown in SEQ ID NO.: 1 or 2.
[0139] As used herein, the term "fusion protein" also includes variant forms of fusion proteins (such as the sequence shown in SEQ ID NO.: 1 or 2) having the above-mentioned activities. These variant forms include (but are not limited to): deletion, insertion and / or substitution of 1-3 (usually 1-2, preferably 1) amino acids, and addition or deletion of one or several (usually within 3, preferably within 2, and more preferably within 1) amino acids at the C-terminus and / or N-terminus. For example, in the art, when amino acids with similar or similar properties are substituted, the function of the protein is usually not changed. For another example, adding or deleting one or several amino acids at the C-terminus and / or N-terminus usually does not change the structure and function of the protein. In addition, the term also includes the polypeptides of the present invention in monomeric and polymeric forms. The term also includes linear and non-linear polypeptides (such as cyclic peptides).
[0140] The present invention also includes active fragments, derivatives and analogs of the above-mentioned fusion proteins. As used herein, the terms "fragment", "derivative" and "analog" refer to polypeptides that substantially retain the function or activity of the fusion protein of the present invention. The polypeptide fragments, derivatives or analogs of the present invention may be (i) polypeptides in which one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) are substituted, or (ii) polypeptides having a substitution group in one or more amino acid residues, or (iii) polypeptides formed by fusion of an antigenic peptide with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol), or (iv) polypeptides formed by fusion of an additional amino acid sequence to this polypeptide sequence (fusion proteins formed by fusion with a leader sequence, a secretory sequence or a tag sequence such as 6×His). According to the teachings herein, these fragments, derivatives and analogs belong to the scope known to those skilled in the art.
[0141] A preferred class of active derivatives refers to polypeptides formed by replacing at most 3, preferably at most 2, and more preferably at most 1 amino acid with similar or similar properties compared to the amino acid sequence of Formula I or Formula II. These conservative variant polypeptides are preferably produced by amino acid substitution according to Table A.
[0142] Table A
[0143] Initial residue Representative replacement Preferred substitutions Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Lys; Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro; Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu; Val; Met; Ala; Phe Leu Leu(L) Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu Phe(F) Leu; Val; Ile; Ala; Tyr Leu Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr; Phe Tyr Tyr(Y) Trp; Phe; Thr; Ser Phe Val(V) Ile; Leu; Met; Phe; Ala Leu
[0144] The present invention also provides analogs of the fusion protein of the present invention. The difference between these analogs and the polypeptide shown in SEQ ID NO.: 1 or SEQ ID NO.: 2 may be a difference in amino acid sequence, or a difference in modification form that does not affect the sequence, or both. Analogs also include analogs with residues different from natural L-amino acids (such as D-amino acids), and analogs with non-natural or synthetic amino acids (such as β, γ-amino acids). It should be understood that the polypeptides of the present invention are not limited to the representative polypeptides exemplified above.
[0145] Modifications (usually without changing the primary structure) include: chemical derivatization of polypeptides in vivo or in vitro, such as acetylation or carboxylation. Modifications also include glycosylation, such as those produced by glycosylation modification during the synthesis and processing of the polypeptide or in further processing steps. This modification can be accomplished by exposing the polypeptide to a glycosylation enzyme (such as a mammalian glycosylase or deglycosylase). Modifications also include sequences with phosphorylated amino acid residues (such as phosphotyrosine, phosphoserine, phosphothreonine). Also included are polypeptides that have been modified to improve their resistance to proteolysis or optimize their solubility.
[0146] Expression vectors and host cells
[0147] The present invention also relates to a vector comprising the polynucleotide of the present invention, a host cell produced by genetic engineering using the vector of the present invention or the coding sequence of the fusion protein of the present invention, and a method for producing the polypeptide of the present invention by recombinant technology.
[0148] The polynucleotide sequence of the present invention can be used to express or produce a recombinant fusion protein by conventional recombinant DNA technology. Generally speaking, there are the following steps:
[0149] (1) Transforming or transducing a suitable host cell with a polynucleotide (or variant) encoding the fusion protein of the present invention, or a recombinant expression vector containing the polynucleotide;
[0150] (2) Host cells cultured in a suitable culture medium;
[0151] (3) Isolate and purify proteins from culture medium or cells.
[0152] In the present invention, the polynucleotide sequence encoding the fusion protein can be inserted into a recombinant expression vector. The term "recombinant expression vector" refers to bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors well known in the art. As long as they can replicate and be stable in the host, any plasmid and vector can be used. An important feature of an expression vector is that it usually contains a replication origin, a promoter, a marker gene and a translation control element.
[0153] Methods well known to those skilled in the art can be used to construct expression vectors containing the DNA sequence encoding the fusion protein of the present invention and appropriate transcription / translation control signals. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. The DNA sequence can be effectively linked to an appropriate promoter in the expression vector to guide mRNA synthesis. Representative examples of these promoters include: lac or trp promoters of Escherichia coli; lambda phage PL promoter; eukaryotic promoters include CMV immediate early promoter, HSV thymidine kinase promoter, early and late SV40 promoter, retroviral LTRs and other known promoters that can control gene expression in prokaryotic or eukaryotic cells or their viruses. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.
[0154] In addition, the expression vector preferably contains one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance and green fluorescent protein (GFP) for eukaryotic cell culture, or tetracycline or ampicillin resistance for Escherichia coli.
[0155] The vector containing the above-mentioned appropriate DNA sequence and an appropriate promoter or control sequence can be used to transform appropriate host cells to enable them to express proteins.
[0156] The host cell can be a prokaryotic cell (such as Escherichia coli), or a lower eukaryotic cell, or a higher eukaryotic cell, such as a yeast cell, a plant cell, or a mammalian cell (including human and non-human mammals). Representative examples include: Escherichia coli, wheat germ cells, insect cells, SF9, Hela, HEK293, CHO, yeast cells, etc. In a preferred embodiment of the present invention, a yeast cell (such as Pichia pastoris, Kluyveromyces, or a combination thereof; preferably, the yeast cell includes: Kluyveromyces, more preferably Kluyveromyces marxianus, and / or Kluyveromyces lactis) is selected as the host cell.
[0157] When the polynucleotide of the present invention is expressed in higher eukaryotic cells, transcription will be enhanced if an enhancer sequence is inserted into the vector. Enhancers are cis-acting factors of DNA, usually about 10 to 300 base pairs, which act on the promoter to enhance gene transcription. Examples include the SV40 enhancer of 100 to 270 base pairs on the late side of the replication origin, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
[0158] Those skilled in the art will appreciate how to select appropriate vectors, promoters, enhancers and host cells.
[0159] Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with CaCl 2 Another method is to use MgCl 2 If necessary, transformation can also be performed by electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0160] The obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0161] The recombinant polypeptide in the above method can be expressed in the cell, on the cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.
[0162] Peptide linker
[0163] The present invention provides a fusion protein, which may optionally contain a peptide linker. The size and complexity of the peptide linker may affect the activity of the protein. Generally, the peptide linker should have sufficient length and flexibility to ensure that the two connected proteins have sufficient spatial freedom to exert their functions. At the same time, the formation of α-helix or β-fold in the peptide linker and the like on the stability of the fusion protein are avoided.
[0164] The length of the connecting peptide is generally 0-20 amino acids, preferably 0-10 amino acids.
[0165] Pharmaceutical composition
[0166] The present invention also provides a pharmaceutical composition. In a preferred embodiment, the composition is a pharmaceutical composition, which contains the above-mentioned fusion protein, and a pharmaceutically acceptable carrier, diluent, stabilizer and / or thickener, and can be prepared into a pharmaceutical type such as lyophilized powder, tablet, capsule, syrup, solution or suspension.
[0167] "Pharmaceutically acceptable carrier or excipient" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the active ingredients of the present invention and with each other without significantly reducing the efficacy of the active ingredients.
[0168] The composition may be a liquid or solid, such as a powder, gel or paste. Preferably, the composition is a liquid, preferably an injectable liquid. Suitable excipients will be known to those skilled in the art.
[0169] Examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0170] The composition may comprise a physiologically acceptable sterile aqueous or anhydrous solution, dispersion, suspension or emulsion, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0171] Typically, these substances are formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH value may vary depending on the nature of the substance being formulated and the condition to be treated. The formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to): intraperitoneal, intravenous, or topical administration. The pharmaceutical composition is used for (i) preventing and / or treating infectious diseases; and / or (ii) preventing and / or treating autoimmune diseases; and / or (iii) preventing and / or treating osteoporosis or loss; and / or (iv) preventing and / or treating tumor-related diseases; and / or (v) inhibiting TNFa-induced apoptosis; and / or (vi) inhibiting TRAIL-induced apoptosis; and / or (vii) inhibiting RANKL-induced differentiation of mononuclear macrophages; and / or (viii) inhibiting TNFa-induced immune activation; and / or (ix) inhibiting RANKL-induced osteoclast formation.
[0172] The main advantages of the present invention include:
[0173] (a) The half-life of the fusion protein of the present invention is long.
[0174] (b) The fusion protein of the present invention can not only improve inflammation in RA patients, but also prevent focal bone erosion and systemic bone loss caused by inflammation.
[0175] (c) The present invention first discovered that the fusion protein of the present invention can significantly (i) prevent and / or treat infectious diseases; and / or (ii) prevent and / or treat autoimmune diseases; and / or (iii) inhibit TNFa-induced cell apoptosis; and / or (iv) inhibit TRAIL-induced cell apoptosis; and / or (v) inhibit RANKL-induced differentiation of mononuclear macrophages; and / or (vi) inhibit osteoporosis and loss caused by autoimmune diseases; and / or (vii) inhibit bone metastases.
[0176] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.
[0177] Unless otherwise specified, the reagents and materials in the examples of the present invention are all commercially available products.
[0178] Example 1 Construction of TNFR2 and OPG IgG Fc fusion protein expression plasmid
[0179] 1. Construction of TNFR2-OPG-Fc fusion protein (hereinafter referred to as OTFc) expression plasmid
[0180] The human OPG gene sequence is from the human OPG full-length cDNA (Open Biosystems, MHS1011-7509022), and the human TNFR2 and human IgG Fc sequences are from the human TNFR2 (1-257)-Fc fusion protein gene, which has been constructed.
[0181] To construct an OPG-TNFR2-Fc fusion protein expression vector, the polymerase chain reaction (PCR) method was first used to synthesize a gene encoding OPG amino acids 1-194 (the 5' and 3' primers were primer-1 and primer-2, respectively, and the primer sequences are shown in Table 1, the same below) using the full-length human OPG cDNA as a template and a gene encoding human TNFR2-Fc fusion protein (excluding protein signal station coding sequence 1-22, 5' and 3' primers were primer-3 and primer-4, respectively) using the human TNFR2 (1-257)-Fc fusion protein gene as a template. The two PCR fragments were then connected by overlapping extension PCR to synthesize a complete gene encoding OPG (1-194)-TNFR2 (23-257)-Fc fusion protein (the 5' and 3' primers were primer-1 and primer-4, respectively). The first 23 nucleotides of primer-2 are complementary to the nucleotide sequence of primer-3, so that the two PCR fragments can be connected in the second step of overlap extension PCR. Primer-1 contains the restriction endonuclease Not I sequence, and primer-4 contains the restriction endonuclease Xba I sequence, which are used for insertion into the protein expression vector. The synthesized PCR fragments were separated by agarose gel electrophoresis and purified using a DNA gel purification kit (QIAGEN). The OPG-TNFR2-Fc fusion protein gene synthesized by overlap extension PCR was first cloned into the pCR2.1 vector (Invitrogen) using a T / A vector cloning kit, and then the fusion protein gene was cut out from this vector using Not I and Xba I restriction endonucleases and inserted into a mammalian cell expression plasmid that was also cut with Not I and Xba I, such as pcDNA3.1 (Invitrogen). The OPG (1-194) -TNFR2 (23-257) -Fc DNA sequence inserted into pCR2.1 was confirmed by DNA sequencing.
[0182] 2. Construction of TNFR2(1-257)-OPG(22-194)-TNFR2(202-257)-Fc (hereinafter referred to as TOFc) fusion protein expression plasmid
[0183] To construct a fusion protein expression vector of TNFR2(1-257)-OPG(22-194)-TNFR2(202-257)-Fc (hereinafter referred to as TNFR2-OPG-Fc), the gene encoding TNFR2 amino acid 1-257 (primers at the 5' and 3' ends are primer-5 and primer-6, respectively), the gene encoding OPG amino acid 22-194 (without the gene encoding protein signal peptide 1-21, primers at the 5' and 3' ends are primer-7 and primer-8, respectively), and the gene encoding Fc (containing TNFR2 amino acid 202-257, primers at the 5' and 3' ends are primer-9 and primer-10, respectively) were synthesized by polymerase chain reaction (PCR) method. The first and second PCR fragments were connected by overlapping extension PCR (the 5' and 3' primers were primer-5 and primer-8, respectively), the second and third PCR fragments were connected (the 5' and 3' primers were primer-7 and primer-4, respectively), and the two PCR fragments were connected by overlapping extension PCR (the 5' and 3' primers were primer-5 and primer-4, respectively) to synthesize the full-length gene encoding TNFR2(1-257)-OPG(22-194)-TNFR2(202-257)-Fc fusion protein OPG-TNFR2-Fc fusion protein. The synthesized fusion protein gene was first cloned into the pCR-Blunt II-TOPO vector (Invitrogen) using a T / A vector cloning kit, and then the fusion protein gene was excised from the vector using Not I and Xba I restriction endonucleases and inserted into a mammalian cell expression plasmid, such as pcDNA3.1 (Invitrogen), which was also digested with Not I and Xba I. The TNFR2 (1-257)-OPG (22-194)-TNFR2 (202-257)-Fc DNA sequence inserted into the pCR-Blunt II-TOPO vector was confirmed by DNA sequencing.
[0184] The schematic diagram of the structure of the two fusion proteins constructed above is as follows Figure 1 shown.
[0185] Table 1
[0186]
[0187] Example 2 Construction of a fusion protein stable expression cell line
[0188] The host cell used to construct cells that stably express fusion proteins is Chinese hamster ovary cells CHO-KS. CHO-KS is a CHO-K1 cell grown in a medium containing fetal bovine serum (FBS). The FBS content in the medium is gradually reduced until it is cultured in a medium without FBS, and finally it is acclimated to cells that grow in suspension in OptiCHO medium (Invitrogen) without FBS. The neomycin-resistant gene in the pcDNA3.1 vector containing the fusion protein gene is replaced with the rat glutamine synthetase gene. The fusion protein expression vector is transfected into CHO-KS cells by electrotransfection (Bio-Rad, Gene Pulser Xcell). After culturing the transfected cells for 24 hours, the transfected cells are screened and cultured on a 96-well culture plate by limiting dilution. The screening medium is OptiCHO, 5μg / ml recombinant human insulin and 10μM aminosulfoxide methionine (MSX). The cells are cultured at 37°C, 8% CO 2 After 3 weeks, the cell culture medium of each well with cell populations was analyzed by ELISA (alkaline phosphatase-conjugated goat anti-human IgG Fc antibody, Jackson ImmunoResearch Lab), and the cell populations expressing fusion protein were further amplified, tested by ELISA, and amplified again to obtain stable cell populations expressing fusion protein.
[0189] Example 3 Expression and purification of fusion protein
[0190] The fusion protein cell line constructed in Example 2 was cultured and expanded to 2 liters. The culture supernatant was harvested and the fusion protein was purified using a Protein-A affinity chromatography column (POROS MabCapture A, Life Tech).
[0191] The purified fusion protein was analyzed by reducing and non-reducing SDS-PAGE electrophoresis and HPLC-SEC (TSKgel G3000SWXL, TOSOH Bioscience).
[0192] Results and Analysis
[0193] OPG-TNFR2-Fc fusion protein is a homodimer with a theoretical molecular weight of about 142 kDa. TNFR2-OPG-Fc fusion protein is a homodimer with a theoretical molecular weight of about 153 kDa. Non-reducing SDS-PAGE electrophoresis gel ( Figure 2 A) shows that the molecular weights of these two homodimeric fusion proteins are greater than that of human immunoglobulin IgG1, and are close to their respective theoretical values. Figure 2 B shows the reducing SDS-PAGE electrophoresis result of the single chain fusion protein.
[0194] The results of HPLC-SEC (molecular sieve chromatography column) analysis of OPG-TNFR2-Fc fusion protein and TNFR2-OPG-Fc fusion protein are shown in Figure 3 The results showed that the fusion protein peak was located near 600 kDa. OPG and TNFR2 each have four cysteine-rich regions (CRDs), and the eight CRDs are linked together to form a rod-like structure for the fusion protein molecule, which showed a molecular weight greater than that of the standard protein with a compact structure in the molecular sieve chromatography column analysis.
[0195] Example 4 In vitro binding study with TNFa
[0196] The in vitro specific binding activity of the fusion protein to TNFa was studied by ELISA. Recombinant human TNFa (rhTNFa, SinoBiological) was dissolved in PBS (pH 7.0) solution, added to a 96-well ELISA plate, and placed in a 4°C refrigerator overnight. The next day, free rhTNFa was washed away with PBST (PBS containing 0.05% Tween-20), and a PBST blocking solution containing 3% BSA was added. Serial dilutions of different concentrations of the fusion protein were added to the blocked ELISA plate, and the fusion protein bound to TNFa was detected with an alkaline phosphatase-coupled goat anti-human IgG Fc antibody (Jackson ImmunoResearch Lab), and a substrate (PNPP) was added for color development, and the plate was read with an ELISA reader at a wavelength of 405nm / 655nm.
[0197] Results and Analysis
[0198] The results of in vitro binding ELISA studies of OPG-TNFR2-Fc fusion protein and TNFR2-OPG-Fc fusion protein with rhTNFa are provided in Figure 4 The results showed that both fusion proteins could bind specifically to rhTNFa. 50 They are 33ng / ml and 68ng / ml respectively.
[0199] Example 5 In vitro binding with RANKL
[0200] The in vitro specific binding activity of the fusion protein to RANKL was studied by ELISA. The recombinant human RANKL-mouse Fc fusion protein (Sino Biological Inc.) was dissolved in PBS (pH 7.0) solution to 1 μg / mL, and 50 μL was added to each well of the 96-well ELISA plate and placed in a refrigerator at 4°C overnight. The next day, the plates were washed three times with PBST (PBS containing 0.05% Tween-20), 200 μL was added to each well, and a PBST blocking solution containing 3% BSA was added. The blocking solution was emptied, and the following three fusion proteins, OPG-TNFR2-Fc, TNFR2-OPG-Fc, and OPG-Fc (Sino Biological Inc., as a control sample) were added to the ELISA plate in serial dilutions. The fusion protein bound to RANKL was detected with alkaline phosphatase-conjugated goat anti-human IgG Fc antibody (Jackson ImmunoResearch Lab), and the substrate (PNPP) was added for color development, and the plate was read at dual wavelengths of 405 nm / 490 nm using an ELISA reader.
[0201] Results and Analysis
[0202] The experimental results show that ( Figure 5 ), all three fusion proteins can bind specifically to human RANKL, but OPG-TNFR2-Fc and TNFR2-OPG-Fc have stronger binding activity to RANKL than OPG-Fc. 50 The binding activity of OPG-TNFR2-Fc and TNFR2-OPG-Fc to RANKL was not significantly different.
[0203] Example 6 In vitro binding with TRAIL
[0204] The in vitro specific binding activity of the fusion protein to TRAIL was studied by ELISA. OPG-TNFR2-Fc, TNFR2-OPG-Fc and OPG-Fc (Sino Biological Inc.) fusion proteins were diluted to 1 μg / mL with PBS, and 50 μL was added to each well of a 96-well ELISA plate and placed in a refrigerator at 4°C overnight. The next day, the plates were washed three times with PBST (PBS containing 0.05% Tween-20), and 200 μL of PBST blocking solution containing 3% BSA was added to each well. The blocking solution was emptied, and serially diluted rhTRAIL (Histidine tag, R&D Systems) was added to the blocked ELISA plate. The rhTRAIL bound to the fusion protein was detected with a mouse anti-Histidine antibody (Sino Biological Inc.) coupled with horseradish peroxidase (HRP), and the substrate (TMB) was added for color development. The plate was read with an ELISA reader at dual wavelengths of 405nm / 490nm.
[0205] Results and Analysis
[0206] The experimental results show that ( Figure 6 ), rhTRAIL can specifically bind to the three fusion proteins, although the binding activity of OPG-TNFR2-Fc and TNFR2-OPG-Fc to TRAIL is weaker than that of OPG-Fc, their binding activity EC 50 The activity of OPG-TNFR2-Fc in binding to TRAIL was slightly stronger than that of TNFR2-OPG-Fc.
[0207] Example 7 Study on the biological activity of TNFR2 in vitro
[0208] The biological activity of TNFR2 of the fusion protein was detected by the biological activity detection method of neutralizing TNFa in vitro. The biological activity of TNFa was detected by mouse fibroblast L929 cytotoxicity. rhTNFa was mixed with different concentrations of fusion proteins, OPG-TNFR2-Fc, TNFR2-OPG-Fc and TNFR2 (Etanercept, Biogen Inc, as a control sample) in a series of dilutions and added to L929 cells. After culturing in a cell culture incubator for 20 hours, the viability of L929 cells was detected by crystal staining method.
[0209] Results and Analysis
[0210] OPG-TNFR2-Fc fusion protein and TNFR2-OPG-Fc fusion protein can inhibit the apoptosis of L929 cells induced by rhTNFa ( Figure 7OPG-TNFR2-Fc inhibited the apoptosis activity of L929 cells induced by TNFa (EC 50 =0.11 nM) is stronger than Etanercept (EC 50 =0.19 nM), and also stronger than TNFR2-OPG-Fc (EC 50 =0.35nM).
[0211] Example 8 Study on the in vitro biological activity of OPG
[0212] 1. Inhibition of TRAIL-induced apoptosis in L929 cells
[0213] Recombinant human TRAIL (R&D Systems Inc.) was mixed with serially diluted fusion proteins of different concentrations and added to L929 cells. After culturing in a cell culture incubator for 20 hours, the viability of L929 cells was detected by crystal staining. Recombinant human OPG-Fc fusion protein (Novo Protein)
[0214] Results and Analysis
[0215] The ability of TNFR2-OPG-Fc fusion protein to inhibit rhTRAIL-induced apoptosis of L929 cells was significantly stronger than that of OPG-Fc and OPG-TNFR2-Fc ( Figure 8 ). The IC50 of TNFR2-OPG-Fc fusion protein in inhibiting rhTRAIL-induced apoptosis of L929 cells was 0.02 nM, and the inhibitory activities of OPG-Fc and OPG-TNFR2-Fc were comparable, with IC50 of 0.27 nM and 0.39 nM, respectively.
[0216] 2. Inhibition of RANKL-induced differentiation of mouse monocyte-macrophage RAW264.7 cells
[0217] The activity of RANKL-induced differentiation of mouse mononuclear macrophage RAW264.7 cells and the activity of OPG-TNFR2-Fc inhibiting RANKL-induced cell differentiation were detected by tartrate-resistant acid phosphate staining (TRAP). Raw264.7 cells (cell bank of the Chinese Academy of Sciences Typical Culture Collection Committee) were cultured in DMEM + 10% FBS medium. One day before the experiment, 100 μL of 5x 10 3cells. After culturing the cells for 24 hours, the supernatant was emptied, and 200 μL-MEM medium + 10% FBS containing 20 ng / mL RANKL and different concentrations of OPG-TNFR2-Fc fusion protein were added to each well. After culturing the cells for 2 days, the supernatant was emptied, and freshly prepared RANKL of the same concentration and OPG-TNFR2-Fc of the corresponding concentration were added, and the cells were cultured for another 3 days. The supernatant was emptied, and the cells were washed twice with PBS solution, and then 100 μL of 1% triton X-100 solution (diluted with PBS) was added to each well to lyse the cells. After high-speed centrifugation, the supernatant was taken, and the content of TRAP in the cell lysate was detected using the TRAP detection kit (Biyuntian Biotechnology Co., Ltd.).
[0218] Results and Analysis
[0219] The experimental results show that ( Fig. 9 ), as the concentration of OPG-TNFR2-Fc fusion protein increased, the content of acid phosphatase produced by RANKL-induced RAW264.7 cells decreased, indicating that OPG-TNFR2-Fc fusion protein can inhibit the differentiation of mouse mononuclear macrophages RAW264.7 induced by RANKL.
[0220] Example 9 Mouse Model Study
[0221] 1. Study on Inhibition of LPS-Induced Septic Shock Death in Mice
[0222] The in vivo biological activity of fusion protein TNFR2 was studied by detecting the effect of fusion protein on LPS-induced septic shock death in mice. 24 8-10 week-old Balb / c mice were divided into 4 groups, with 6 mice in each group (half male and half female). Each mouse was intraperitoneally injected with 1 mg LPS, followed by intravenous injection of different doses of TNFR2-OPG-Fc fusion protein and Etanercept (Pfize). The status of the mice was observed in the following 2 days, and the time of death of the mice was recorded.
[0223] Results and Analysis
[0224] After the lethal dose of 1mg LPS was injected, all mice in the control group died within 26 hours. Two mice and two mice in the two groups injected with 100μg and 150μg of TNFR2-OPG-Fc fusion protein respectively survived, and one and two mice respectively survived at 46 hours. All mice injected with 100μg of TNFR2-Fc (Etanercept) (equivalent to 150μg of TNFR2-OPG-Fc) also died within 26 hours ( Fig.10 ).
[0225] 2. CIA-induced arthritis model in mice
[0226] The methods for establishing the CIA mouse arthritis model refer to Feige et al., Cell Mol Life Sci, 57: 1457-1470, 2000 and Schett et al., Arthritis Rheum. 52: 1604-1611, 2005. The CIA model mice were randomly divided into 4 groups, namely, the negative control group (group 1, no immunization, no medication), the positive control group (group 2, immunization but no medication), the Etanercept group (group 3, 25 mg / kg) and the OGP-TNFR2-Fc fusion protein group (group 4, 30 mg / kg, the molar content is equivalent to 25 mg / kg of Etanercept), each group containing 8 mice. The mice in groups 1-3 were immunized twice at D1 and D22, respectively, and then the mice in groups 3 and 4 were intraperitoneally injected with the corresponding fusion protein, 3 times a week, for a total of 11 times.
[0227] The clinical symptoms of mice were detected as follows:
[0228] At the end of the second immunization of the animals on D22, clinical joint scoring was started, and clinical scoring was performed 3 times a week. The clinical scoring criteria are as follows:
[0229]
[0230] The degree of inflammatory cell infiltration in the ankle and vertebrae of each group of mice was evaluated. Serum was collected at D35 and 24 hours after the last administration. The ankle joint of the right hind paw was collected at the end point, fixed with 4% paraformaldehyde, and sliced for HE staining after decalcification for histopathological scoring. The parameters of cell infiltration, bone erosion, and cartilage damage were graded separately.
[0231] Bone density (BMD) evaluation: At the end of the experiment, the left posterior bone and vertebrae were taken and dehydrated by soaking in 70% ethanol, and the bone density was measured by micro-CT.
[0232] Results and Analysis
[0233] The results of this experiment showed that at the end of the experiment, all mice in the positive control group showed symptoms of arthritis in their paws, while the incidence of inflammation in the mice in the OPG-TNFR2-Fc and etanercept groups was between 50-60% ( Fig.11A The clinical scoring results of mouse paw inflammation showed that the average degree of inflammation in the paws of mice in the OPG-TNFR2-Fc group was significantly lower than that of mice in the positive control group, and was comparable to the degree of inflammation shown by mice in the etanercept group ( Fig. 11B ). The results of this experiment prove that OPG-TNFR2-Fc fusion protein has a good function of protecting and reducing the degree of arthritis in mice induced by CIA.
[0234] Example 10 Study on the effect of OPG-TNFR2-Fc fusion protein on bone absorption in cynomolgus monkeys The effect of OPG-TNFR2-Fc fusion protein on the concentration of tartrate-resistant acid phosphatase-5b (TRAP-5b) in cynomolgus monkey serum was studied to study the effect of fusion protein on bone absorption in cynomolgus monkeys. TRAP-5b is a metabolite in the process of bone absorption and is used as a biomarker for bone absorption. Six male cynomolgus monkeys (3 to 5 years old) were divided into three groups, one of which was intravenously administered with 15 mg / kg of OPG-TNFR2-Fc fusion protein, and the other two groups were subcutaneously injected with 5 mg / kg and 15 mg / kg of OPG-TNFR2-Fc fusion protein, respectively. Blood was collected at the following times to retain serum: before administration, 24 hours, 48 hours and 168 hours after administration. The concentration of TRAP-5b in serum was detected using a TRAP-5b detection kit (Shanghai BlueGene Biotechnology Co., Ltd.)
[0235] Results and Analysis
[0236] Table 2 shows studies on reducing the concentration of the bone resorption marker TRAP-5b in cynomolgus monkey serum.
[0237] Table 2
[0238]
[0239] The results of the study showed (Table 2) that 24 hours after administration of OPG-TNFR2-Fc fusion protein, the concentration of TRAP-5b in the serum of all cynomolgus monkeys decreased, ranging from 11% to 40%. In the subcutaneous administration group, the degree of reduction in TRAP-5b concentration was proportional to the dose. After 24, 48 and 168 hours after administration, the average concentration of TRAP-5b in the serum of all cynomolgus monkeys decreased by 24%, 11% and 8%, respectively. This study shows that OPG-TNFR2-Fc fusion protein can inhibit bone resorption in cynomolgus monkeys.
[0240] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A fusion protein, a polynucleotide encoding the fusion protein, a vector, and a host cell, characterized in that: For preparing a composition or preparation for (i) preventing and / or treating infectious diseases; and / or (ii) preventing and / or treating tumor-related diseases; The fusion protein comprises the following elements fused together: (a) TNF receptor or its active fragment; (b) OPG or its active fragment; and (c) Fc fragment; The vector contains a polynucleotide encoding the fusion protein, and the host cell contains the vector or has the polynucleotide encoding the fusion protein integrated into its genome.
2. The use according to claim 1, characterized in that The TNF receptor is selected from the group consisting of TNFR2, TNFR1, or a combination thereof.
3. The use according to claim 1, characterized in that The Fc fragment is the Fc fragment of immunoglobulin IgG, preferably the Fc part of IgG1.
4. The use according to claim 1, characterized in that The Fc fragment contains or has the 99th (Glu)-330th (Lys) position of the human IgG1 amino acid sequence (accession number is UniProtKB-P01857).
5. The use according to claim 1, characterized in that The Fc fragment contains or has positions 487-718 of SEQ ID NO.:
1.
6. The use according to claim 1, characterized in that The fusion protein has a structure shown in the following formula I or II: XYZ(I) YXZ(II); In the formula, X is a TNF receptor or an active fragment thereof; Y is OPG or an active fragment thereof; Z is an Fc fragment; "-" represents a peptide bond or a peptide linker connecting the above elements.
7. The use according to claim 6, characterized in that In formula I, the amino acid sequence of XY is shown in positions 1-486 of SEQ ID NO.
1.
8. The use according to claim 6, characterized in that In formula II, the amino acid sequence of YX is shown in positions 1-429 of SEQ ID NO.
2.
9. The use according to claim 1, characterized in that The amino acid sequence of the fusion protein is shown in SEQ ID NO.: 1 or 2.
10. The use according to claim 1, characterized in that The infectious disease includes septic shock (such as LPS-induced septic shock).
11. The use according to claim 1, characterized in that The tumor-related disease is selected from the group consisting of multiple myeloma, bone-related bone metastatic solid tumors, or a combination thereof.
